Minute Insight: Abbott Receives US FDA Clearance For Spinal Cord Stimulator
Abbott announced on 19 December that the US Food and Drug Administration has approved its Eterna spinal cord stimulation system (SCS) for treating chronic pain with low-dose BURSTDR stimulation.
You may also be interested in...
Minute Insight: Abbott Wins Expanded FDA Approval For Proclaim XR Spinal Cord Stimulator For Diabetic Peripheral Neuropathy
Abbott said a major competitive benefit of the Proclaim XR SCS system is the battery life of up to 10 years at low settings.
In this month’s Digital Health Roundup, Medtech Insight’s Marion Webb provides highlights from the recent CES 2023 conference in Las Vegas. Reed Miller discusses Abbott’s VR partnership with the Blood Centers for America and Barnaby Pickering highlights Bayer’s jump into medtech with its buyout of Blackford Analysis.
In this final roundup of innovative health technologies showcased at CES 2023, Medtech Insight highlights three companies, Biobeat, Conneqt and Valencell, that are developing innovative technologies for cuffless blood pressure monitoring. Biobeat is the first company to receive US FDA clearance for a wearable to monitor blood pressure, but competition looms.